These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

394 related articles for article (PubMed ID: 26652126)

  • 1. Resident Physicians Choices of Anticoagulation for Stroke Prevention in Patients With Nonvalvular Atrial Fibrillation.
    Oqab Z; McIntyre WF; Quinn KL; Lamb T; Quadros K; Yazdan-Ashoori P; van Oosten E; Chu K; Lamba J; Barake W; Mohajer K; Marr JN; Baranchuk A
    Can J Cardiol; 2016 Jun; 32(6):824-8. PubMed ID: 26652126
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The anticoagulation choices of internal medicine residents for stroke prevention in non-valvular atrial fibrillation.
    Moulson N; McIntyre WF; Oqab Z; Yazdan-Ashoori P; Quinn KL; van Oosten E; Hopman WM; Baranchuk A
    Postgrad Med J; 2017 Jun; 93(1100):308-312. PubMed ID: 27307471
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Indirect Comparison of Novel Oral Anticoagulants in Women with Nonvalvular Atrial Fibrillation.
    Moseley A; Doukky R; Williams KA; Jaffer AK; Volgman AS
    J Womens Health (Larchmt); 2017 Mar; 26(3):214-221. PubMed ID: 27870603
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of non-vitamin K antagonist oral anticoagulants in atrial fibrillation patients: insights from a specialist atrial fibrillation clinic.
    Lee SI; Sayers M; Lip GY; Lane DA
    Int J Clin Pract; 2015 Nov; 69(11):1341-8. PubMed ID: 26234557
    [TBL] [Abstract][Full Text] [Related]  

  • 5. How do family medicine residents choose an anticoagulation regimen for patients with nonvalvular atrial fibrillation?
    Yazdan-Ashoori P; Oqab Z; McIntyre WF; Quinn KL; Oosten EV; Hopman WM; Baranchuk A
    Prim Health Care Res Dev; 2017 Sep; 18(5):472-481. PubMed ID: 28464979
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness and Safety of Apixaban, Dabigatran, and Rivaroxaban Versus Warfarin in Patients With Nonvalvular Atrial Fibrillation and Previous Stroke or Transient Ischemic Attack.
    Coleman CI; Peacock WF; Bunz TJ; Alberts MJ
    Stroke; 2017 Aug; 48(8):2142-2149. PubMed ID: 28655814
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Factors associated with non-vitamin K antagonist oral anticoagulants for stroke prevention in patients with new-onset atrial fibrillation: Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT-AF II).
    Steinberg BA; Shrader P; Thomas L; Ansell J; Fonarow GC; Gersh BJ; Hylek E; Kowey PR; Mahaffey KW; O'Brien EC; Singer DE; Peterson ED; Piccini JP;
    Am Heart J; 2017 Jul; 189():40-47. PubMed ID: 28625380
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oral Anticoagulants to Prevent Stroke in Nonvalvular Atrial Fibrillation in Patients With CKD Stage 5D: An NKF-KDOQI Controversies Report.
    Bansal VK; Herzog CA; Sarnak MJ; Choi MJ; Mehta R; Jaar BG; Rocco MV; Kramer H
    Am J Kidney Dis; 2017 Dec; 70(6):859-868. PubMed ID: 28941763
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel oral anticoagulants for stroke prevention in atrial fibrillation: focus on apixaban.
    Potpara TS; Polovina MM; Licina MM; Stojanovic RM; Prostran MS; Lip GY
    Adv Ther; 2012 Jun; 29(6):491-507. PubMed ID: 22684583
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-Effectiveness of Novel Oral Anticoagulants for Stroke Prevention in Non-Valvular Atrial Fibrillation.
    Singh SM; Wijeysundera HC
    Curr Cardiol Rep; 2015 Aug; 17(8):61. PubMed ID: 26081245
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Higher Incidence of Ischemic Stroke in Patients Taking Novel Oral Anticoagulants.
    Shpak M; Ramakrishnan A; Nadasdy Z; Cowperthwaite M; Fanale C
    Stroke; 2018 Dec; 49(12):2851-2856. PubMed ID: 30571404
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Non-vitamin K antagonist oral anticoagulation agents in anticoagulant naïve atrial fibrillation patients: Danish nationwide descriptive data 2011-2013.
    Olesen JB; Sørensen R; Hansen ML; Lamberts M; Weeke P; Mikkelsen AP; Køber L; Gislason GH; Torp-Pedersen C; Fosbøl EL
    Europace; 2015 Feb; 17(2):187-93. PubMed ID: 25236181
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Trends in Prescribing Oral Anticoagulants in Canada, 2008-2014.
    Weitz JI; Semchuk W; Turpie AG; Fisher WD; Kong C; Ciaccia A; Cairns JA
    Clin Ther; 2015 Nov; 37(11):2506-2514.e4. PubMed ID: 26481493
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nonvitamin K-dependent oral anticoagulants (NOACs) in chronic kidney disease patients with atrial fibrillation.
    Di Lullo L; Ronco C; Cozzolino M; Russo D; Russo L; Di Iorio B; De Pascalis A; Barbera V; Galliani M; Vitaliano E; Campana C; Santoboni F; Bellasi A
    Thromb Res; 2017 Jul; 155():38-47. PubMed ID: 28482261
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Temporal Trends in the Use and Comparative Effectiveness of Direct Oral Anticoagulant Agents Versus Warfarin for Nonvalvular Atrial Fibrillation: A Canadian Population-Based Study.
    Yu AYX; Malo S; Svenson LW; Wilton SB; Hill MD
    J Am Heart Assoc; 2017 Oct; 6(11):. PubMed ID: 29080863
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Approach to the new oral anticoagulants in family practice: part 1: comparing the options.
    Douketis J; Bell AD; Eikelboom J; Liew A
    Can Fam Physician; 2014 Nov; 60(11):989-95. PubMed ID: 25392438
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment of Web-based education resources informing patients about stroke prevention in atrial fibrillation.
    Pandya E; Bajorek BV
    J Clin Pharm Ther; 2016 Dec; 41(6):667-676. PubMed ID: 27704588
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current trial-associated outcomes with warfarin in prevention of stroke in patients with nonvalvular atrial fibrillation: a meta-analysis.
    Agarwal S; Hachamovitch R; Menon V
    Arch Intern Med; 2012 Apr; 172(8):623-31; discussion 631-3. PubMed ID: 22450212
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Values and Preferences of Physicians and Patients With Nonvalvular Atrial Fibrillation Who Receive Oral Anticoagulation Therapy for Stroke Prevention.
    Andrade JG; Krahn AD; Skanes AC; Purdham D; Ciaccia A; Connors S
    Can J Cardiol; 2016 Jun; 32(6):747-53. PubMed ID: 26774235
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Non-vitamin K Oral Anticoagulants Versus Warfarin for Patients with Atrial Fibrillation: Absolute Benefit and Harm Assessments Yield Novel Insights.
    Kumana CR; Cheung BM; Siu DC; Tse HF; Lauder IJ
    Cardiovasc Ther; 2016 Apr; 34(2):100-6. PubMed ID: 26727005
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.